A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)

• Published in: International Urogynecology Journal 2018-02, Vol.29 (2), p.273-283
• Main Authors: Staskin, David, Herschorn, Sender, Fialkov, Jonathan, Tu, Le Mai, Walsh, Terry, Schermer, Carol R.
• Format: Article
• Language: English
• Subjects: Acetanilides - therapeutic use; Adult; Aged; Cross-Over Studies; Double-Blind Method; Double-blind studies; Female; Gynecology; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Original; Original Article; Patient Preference; Patients; Prospective Studies; Thiazoles - therapeutic use; Tolterodine Tartrate - therapeutic use; Treatment Outcome; Urinary Bladder, Overactive - drug therapy; Urinary Bladder, Overactive - psychology; Urological Agents - therapeutic use; Urology
• ISSN: 0937-3462; 1433-3023
• DOI: 10.1007/s00192-017-3377-5

Introduction and hypothesis The objective of this study was to assess the tolerability and treatment preference in patients with overactive bladder (OAB) treated with mirabegron or tolterodine. Methods This was a two-period, 8-week crossover, double-blind, phase IV study (PREFER; NCT02138747) in treatment-naive adults with OAB for 3 months or longer randomized to one of four treatment sequences in a 5:5:1:1 ratio (mirabegron/tolterodine, tolterodine/mirabegron, mirabegron/mirabegron, or tolterodine/tolterodine), separated by a washout period of 2 weeks. The primary endpoint was drug tolerability using the Medication Tolerability scale of the OAB Treatment Satisfaction (OAB-S) questionnaire at end of treatment (EoT). Period-by-treatment interactions were analyzed to determine any effect of drug order. Patient preference, change from baseline in OAB symptoms, and treatment-emergent adverse events (TEAEs) were assessed. Results A total of 358 randomized patients completed the OAB-S Medication Tolerability scale questionnaire at one or more visits after the baseline evaluation. The mean (95% CI) OAB-S Medication Tolerability scores were significantly higher (better tolerability) for mirabegron (86.29 [83.50, 89.08]) than for tolterodine (83.40 [80.59, 86.20]; p  = 0.004). The period-by-treatment interaction was not significant ( p  = 0.955). Improvements in OAB-S Medication Tolerability scores at EoT were more evident in women, patients aged ≥65 years, and in patients without baseline incontinence, and were greater with mirabegron than with tolterodine extended release. There were no significant differences in patient preference or improvements in OAB symptoms. Significant differences in favor of mirabegron were observed for anticholinergic TEAEs (20.4% vs. 27.4%; p  = 0.042) and specifically for gastrointestinal disorders (14.7% vs. 22.5%; p  = 0.015). Conclusions Tolerability of mirabegron was significantly higher than that of tolterodine, and patient preference and improvements in OAB symptoms were comparable. Both treatments were well tolerated; however, anticholinergic side effects were higher with tolterodine.